Earnings Call Intelligence Subscribe
Home › Call Sheets › ABBV › Q3'26
Call sheet · Q3'26

AbbVie (ABBV)

Q3'26 earnings call · held October 30, 2026 · compared with the Q2'26 call · management-credibility review
8/12
Disclosure score
4 medium, 4 low flags
Financial quality
Bottom line
The headline is clean beat-and-raise: revenue $17.4B (+10.5%), EPS $3.82 (+7c), third consecutive Skyrizzy guidance raise this year. But look at the full-year EPS guidance midpoint: it's $13.97 this quarter and it was $13.97 last quarter, meaning the 7-cent beat simply disappeared into the model rather than flowing through, a sleeper tell that the market isn't pricing. The binding constraint on the next leg of growth isn't demand (Skyrizzy/Rinvoq combined are doing $6B of incremental growth this year), it's payer contract cycles and Medicare timing: management conceded outright in Q&A that 'we've missed sort of the Medicare window for 27' on Juvemo, pushing broad coverage to 2028. My view changes if management provides a clear EPS bridge next quarter explaining where the beat went, and if the Skyrizzy NBRX/MBRX trend data that disappeared this quarter comes back with numbers that still support the '1-in-2' capture claim.

The 30-second version

  • The 'raise' that isn't: full-year EPS midpoint hasn't moved an inch since Q2
  • Beat-and-raise headline is real, but the binding constraint is payer/Medicare timing, not demand
  • The Skyrizzy psoriasis share proof point got vaguer, not more precise

What changed this quarter

MetricQ2'26Q3'26Change
Total Net Revenue~$17.0B, +10.2% op.$17.4B, +10.5% op.+30bps growth acceleration
Adjusted EPS$3.65, +6c vs guide midpoint$3.82, +7c vs guide midpoint+17c QoQ beat widened
FY Adjusted EPS Guidance Midpoint$13.87-$14.07, midpoint $13.97$13.95-$13.99, midpoint $13.97Flat midpoint despite 'raise' framing
FY Revenue Guidance~$67.6B (+$300M raise)~$67.8B (+$200M raise)Smaller incremental raise than Q2
Adjusted Gross Margin84.7%85.1%+40bps expansion
Adjusted Operating Margin48.3% (incl. 1.7% IPR&D drag)48.7% (incl. 1.2% IPR&D drag)+40bps, less IPR&D drag
Acquired IPR&D EPS Drag17c unfavorable11c unfavorableSmaller drag, still recurring and excluded from guidance
Immunology Segment Revenue$8.8B, +14.6%$9.2B, +16.6%+200bps acceleration
Skyrizzy Sales Growth$5.5B, +24.0%$5.8B, +22.9%Modest deceleration off larger base
Rinvoq Sales Growth$2.5B, +23.7%$2.7B, +24.3%+60bps acceleration

Accountability tracked

8 new promises made5 narrative shifts flagged8 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full ABBV Q3'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.